Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Book chapter
Title: Pharmacotherapies for cannabis use disorders: Clinical challenges and promising therapeutic agents
Author: Nielsen, S.
Sabioni, P.
Gowing, L.
Le Foll, B.
Citation: Substance Use Disorders: From Etiology to Treatment, 2020 / Nadar, M.A., Hurd, Y.L. (ed./s), vol.258, Ch.13, pp.355-372
Publisher: Springer
Publisher Place: Cham, Switzerland
Issue Date: 2020
Series/Report no.: Handbook of Experimental Pharmacology; 258
ISBN: 3030336786
Editor: Nadar, M.A.
Hurd, Y.L.
Statement of
Suzanne Nielsen, Pamela Sabioni, Linda Gowing, and Bernard Le Foll
Abstract: This chapter reviews pharmacotherapies that have been trialled for cannabis dependence, identifying those that warrant further research and those of little or uncertain value. A diverse range of medicines have been tested, representing a broad range of pharmacological strategies. These include tetrahydrocannabinol preparations, various types of antidepressant, anxiolytics, a glutamatergic modulator and the neuropeptide oxytocin. Cannabinoid agonists warrant further research. For the FAAH inhibitor PF-04457845, oxytocin, varenicline and gabapentin, although there is a signal to indicate further research is warranted, these medications do not yet have sufficient evidence to support clinical use, and larger, longer-term trials are needed in representative treatment-seeking populations. Special populations that warrant consideration are those with cannabis dependence and concurrent mental health conditions and those that develop dependence through therapeutic use.
Keywords: Cannabis; Cannabis dependence; Cannabis use disorder; Pharmacotherapy; Treatment
Rights: © Springer Nature Switzerland AG 2019
DOI: 10.1007/164_2019_258
Published version:
Appears in Collections:Aurora harvest 4
Pharmacology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.